Physician profile
James S Bear
NPI 1346467230
$386.73
in general payments reported to CMS, 2019-2025
14 companies · $36.24 in 2025
The $36.24 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $43.92 · 2021: $26.48 · 2023: $48.79 · 2024: $58.84 · 2025: $36.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $143.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $91.65 | 2019-2020 | |
| Glaxosmithkline, LLC. | $45.95 | 2019-2025 | Shingrix, Penmenvy, Bexsero |
| Myriad Genetic Laboratories, INC. | $32.12 | 2024 | Myrisk |
| Pfizer INC. | $31.29 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $30.32 | 2019 | |
| Amgen INC. | $29.67 | 2019-2025 | Repatha, Otezla |
| Lilly USA, LLC | $25.15 | 2019-2020 | |
| Allergan, INC. | $17.92 | 2019 | |
| Abbvie INC. | $17.50 | 2023 | Synthroid, Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.80 | 2024 | Xifaxan |
| Astellas Pharma US INC | $14.17 | 2021 | |
| Mylan Specialty L.P. | $13.36 | 2019 | |
| Dynavax Technologies Corporation | $11.92 | 2024 | Heplisav-B |
| Abbott Laboratories | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.